Aortic & peripheral vascular disease
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.86 95% CI 0.84–0.89Authors' conclusion
In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease.
Study context
- Population
- Patients undergoing endovascular revascularization (≥1 balloon and/or stent) for lower limb PAD, French National Healthcare System, Oct 2011–Dec 2019analysed
- Participants
- 259,137 patients
- Exposure
- PCD vs no PCD for lower limb endovascular revascularization
- PCDn = 20,083
- Outcome
- All-cause mortality
- Follow-up
- Until December 31, 2021; median 4.1 years (Q1-Q3: 2.3-6.4 years)
Methodological detailsnationwide, medico-administrative data, propensity score matching (sensitivity)
- Nationwide
- Medico-administrative data
- Propensity score matching (sensitivity)
Main finding
As reported in the abstract
median follow-up 4.1 years
Hazard ratio
0.86
95% CI 0.84–0.89
P < 0.001
Events by group
PCD
5,385
events
Control
109,844
events
PCDvs Control
HR 0.86 (95% CI 0.84–0.89); P < 0.001
Observational data: associations, not effects.
Original publication
Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease. J Am Coll Cardiol. Published 25 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →